Defining a comprehensive set of value assessment criteria for funders of drug repurposing initiatives.

Authors

Dalma Hosszú, Kristóf Gyöngyösi, András Perényi, Helene G van der Meer, Dunja Huijbers, Pan Pantziarka, András Inotai, Donald C Lo, Rick Thompson, Zoltán Kaló, Marcell Csanádi

Published in

British journal of clinical pharmacology. Oct 07, 2026. Epub Oct 07, 2026.

Abstract

This study aims to develop a structured list of value assessment criteria for drug repurposing (DR) projects designed to support consistent, evidence-informed decision-making by funders. The assessment criteria were developed within the REMEDi4ALL project, a multi-stakeholder Horizon Europe funded initiative to advance DR and were validated through consultation with public and philanthropic funding organizations.
Relevant assessment criteria were identified through a review of organizational documents and stakeholder consultations and were further supplemented by a targeted literature search in PubMed and Google Scholar.
A total of 330 candidate criteria were identified from funder documentation and peer-reviewed literature. Following internal review and consultation with additional REMEDi4ALL partner organizations, 37 assessment criteria were defined and organized into five domains: basic enablers, expected benefits, technical implementation, business opportunity and fundraising profile. Each criterion was assigned a clear, standardized definition to ensure consistent interpretation and application.
This study presents a transparent, adaptable and non-proprietary set of value assessment criteria to support the evaluation of DR proposals. It addresses key methodological and applicability gaps by enabling funders to apply structured assessments that reflect diverse value perspectives and stages of development in standalone or joint funding settings. The criteria list is clearly defined and grouped into five domains that also serves as the core for further application. The list has already been implemented in an Excel-based application to select, weight and score items based on funder's strategic priorities and project maturity. It is freely available through the REMEDi4ALL platform.

PMID:
42844884
Bibliographic data and abstract were imported from PubMed on 08 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.